Reza-Thierry Elaidi

5PUBLICATIONS
37CO-AUTHORS
Predictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (5)

|Dec 09, 2023
Longitudinal Study of Advanced Non-Small Cell Lung Cancer with Initial Durable Clinical Benefit to Immunotherapy: Strategies for Anti-PD-1/PD-L1 Continuation beyond Progression.

Ivan Pourmir, Reza Elaidi, Zineb Maaradji

|Jun 19, 2023
Mesenchymal-like Tumor Cells and Myofibroblastic Cancer-Associated Fibroblasts Are Associated with Progression and Immunotherapy Response of Clear Cell Renal Cell Carcinoma.

Guillaume Davidson, Alexandra Helleux, Yann A Vano

|Nov 14, 2022
An Enhancer Demethylator Phenotype Converged to Immune Dysfunction and Resistance to Immune Checkpoint Inhibitors in Clear-Cell Renal Cell Carcinomas.

Xiaofan Lu, Yann Vano, Alexandra Helleux

|Feb 15, 2022
Modeled Early Longitudinal PSA Kinetics Prognostic Value in Rising PSA Prostate Cancer Patients after Local Therapy Treated with ADT +/- Docetaxel.

Aurore Carrot, Reza-Thierry Elaidi, Olivier Colomban

|Jul 01, 2020
Comparative Efficacy of First-Line Immune-Based Combination Therapies in Metastatic Renal Cell Carcinoma: A Systematic Review and Network Meta-Analysis.

Reza Elaidi, Letuan Phan, Delphine Borchiellini

Pageof 1

Frequent Collaborators

3 joint publications

Yann Vano

3 joint publications

Stéphane Oudard

2 joint publications

Mostefa Bennamoun

2 joint publications

Christine Chevreau